Literature DB >> 19356768

Effects of verapamil on anterior ST segment and ventricular fibrillation cycle length in patients with Brugada syndrome.

Masaomi Chinushi1, Kenichi Iijima, Minoru Tagawa, Satoru Komura, Hiroshi Furushima, Yoshifusa Aizawa.   

Abstract

PURPOSE: This study examined the effects of verapamil (5-10 mg intravenous) on the cardiac electrical activity of 10 Brugada syndrome (BS) patients having vasospastic angina, atrial fibrillation, and/or hypertension.
RESULTS: Verapamil showed no significant change in the ST-segment elevation. Likewise, there was no significant change in the lengths of QRS complex, HV and corrected QT intervals, or effective refractory period at the right ventricle. The conduction time between right ventricular apex and outflow tract, measured at 400-millisecond pacing, was mildly prolonged by verapamil. At baseline, induced ventricular fibrillation (VF) was terminated by a 200-J shock in all patients. After verapamil, VF was reinduced in 7, was noninducible in 2, and self-terminated in 1 patient. Mean F-F interval was shorter after than before verapamil, and a 360-J shock was required in 2 of the 7 patients.
CONCLUSION: In some BS patients, calcium channel blockade may modify the electrical characteristics of VF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19356768     DOI: 10.1016/j.jelectrocard.2009.03.009

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN: 0022-0736            Impact factor:   1.438


  3 in total

1.  A case of Brugada syndrome coexisting with vasospastic angina: Caution should be taken when using calcium channel blockers.

Authors:  Takahisa Yoshikawa; Chisato Izumi; Kazuaki Kaitani; Yoshihisa Nakagawa
Journal:  J Cardiol Cases       Date:  2011-10-02

2.  Bepridil monotherapy failed to prevent coronary vasospasm in a Brugada syndrome patient.

Authors:  Takuro Kazatani; Akinori Higaki; Yuta Tanaka; Yoshitaka Kawada; Go Hiasa; Tadakatsu Yamada; Hideki Okayama
Journal:  Oxf Med Case Reports       Date:  2022-08-18

3.  Ageing and Brugada syndrome: considerations and recommendations.

Authors:  Pieter G Postema; Hanno L Tan; Arthur Am Wilde
Journal:  J Geriatr Cardiol       Date:  2013-03       Impact factor: 3.327

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.